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ABSTRACT
Accumulating evidences indicate that different long non-coding RNAs (lncRNAs) 
might play a relevant role in tumorigenesis, with their expression and function 
already associated to cancer development and progression. CCAAT/enhancer-binding 
protein-α (CEBPA) is a critical regulator of myeloid differentiation whose inactivation 
contributes to the development of acute myeloid leukemia (AML). Mutations in C/EBPα 
occur in around 10% of AML cases, leading to the expression of a 30-kDa dominant 
negative isoform (C/EBPα-p30). In this study, we identified the oncogenic urothelial 
carcinoma associated 1 (UCA1) lncRNA as a novel target of the C/EBPα-p30. We show 
that wild-type C/EBPα and C/EBPα-p30 isoform can bind the UCA1 promoter but have 
opposite effects on UCA1 expression. While wild-type C/EBPα represses, C/EBPα-p30 
can induce UCA1 transcription. Notably, we also show that UCA1 expression increases 
in cytogenetically normal AML cases carrying biallelic CEBPA mutations. Furthermore, 
we demonstrate that UCA1 sustains proliferation of AML cells by repressing the 
expression of the cell cycle regulator p27kip1. Thus, we identified, for the first time, 
an oncogenic lncRNA functioning in concert with the dominant negative isoform of 
C/EBPα in AML.
INTRODUCTION
Blocks in genetic programs required for terminal 
myeloid differentiation and aberrant proliferation 
characterize acute myeloid leukemia (AML) (reviewed in 
[1]). One of the key components that have been shown to 
be crucial for myeloid differentiation is the transcription 
factor CCAAT/enhancer-binding protein-α (C/EBPα) 
(reviewed in [2]). The intronless CEBPA mRNA can 
produce two translation products by using two different 
start codons within the same open reading frame: the full-
length C/EBPα (p42) and a shorter form (p30) (reviewed 
in [3]). P30 isoform retains the DNA-binding domain, but 
lacks the N-terminal transactivation domain and exhibits a 
dominant-negative function over p42 isoform. Furthermore, 
independent or different p30 functions than that of p42 
have been described in transcriptional regulation indicating 
that this isoform is more than just a dominant-negative 
regulator of p42 [4–7]. Specifically, p30 was shown to act as 
transcriptional activator of the PIN1 [6] and miR-181a [7] 
genes. The ratio of p30/p42 is critical for granulopoiesis as 
the p30 protein fails to induce differentiation and increases 
cell proliferation of myeloid progenitors [3, 8]. Relative 
levels of the two isoforms are controlled at the translational 
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level to respond to extracellular conditions [3]. In AML, 
C/EBPα function is frequently disrupted by mutations in 
its locus or by the action of leukaemogenic fusion proteins 
[2, 3, 9]. In particular, approximately 10% of AML patients 
show dominant-negative mutations in the CEBPA coding 
region that in most of the cases abolish translation of full-
length C/EBPα, leading to overexpression of the shorter 
p30 isoform [3, 8]. Notably, mouse models have shown that 
it is the increased expression of the p30 isoform, and not 
the loss of wild type C/EBPα, to be required for leukemia 
transformation [10]. Various downstream effectors have 
been shown to contribute to C/EBPα p42 and p30 activity, 
including non-coding RNAs (ncRNAs). At present, the 
majority of the studies have mainly focused on microRNAs 
[11–14]. These investigations showed that deregulation of 
specific C/EBPα-regulated microRNAs plays a critical role 
in leukemia initiation and outcome prediction. However, 
current studies on human transcriptome have shown 
that a relevant part of the genome is transcribed in the 
heterogeneous class of long non-coding RNAs (lncRNAs). 
Similarly to microRNAs, lncRNAs may have important 
functions in regulatory networks controlling diverse 
cellular processes, with their expression already associated 
with disorders, including cancer [15–17]. Thus, studying 
the expression and function of lncRNAs could help our 
understanding of leukemogenenis and in the identification 
of novel therapeutic targets. Different lncRNAs have been 
identified in normal and malignant hematopoiesis [18]. 
However, only a few have been identified and functionally 
characterized in the context of the AML-associated aberrant 
transcriptional programs [19, 20].
We therefore performed a genome-wide transcriptome 
analysis by RNA-sequencing to identify lncRNAs 
specifically regulated by the p30 isoform of C/EBPα. Among 
them, we identified the oncogenic urothelial carcinoma 
associated 1 (UCA1) lncRNA [21–24]. We showed that 
both wild-type C/EBPα and C/EBPα-p30 isoforms can bind 
the UCA1 promoter but have opposite effects on UCA1 
expression. While wild-type C/EBPα repressed, C/EBPα-p30 
strongly induced UCA1 transcription. Furthermore, we 
demonstrated that UCA1 sustains proliferation of AML 
cells by repressing the expression of the cell cycle regulator 
p27kip1. Notably, we also show that UCA1 expression is 
increased in primary cells from cytogenetically normal 
AML carrying biallelic CEBPA mutations. Therein, our 
findings indicate UCA1 as a novel diagnostic biomarker and 
a potential target for AML with CEBPA mutations.
RESULTS
UCA1 transcripts is specifically induced by 
C/EBPα-p30 and up-regulated in AML with 
CEBPA mutations
To investigate the regulation of lncRNAs by the p30 
dominant negative isoform of C/EBPα, we utilized the 
leukemic K562 cells, which do not express neither of the 
two C/EBPα isoforms, stably transformed with a PiggyBac 
transposon system [25] carrying Tet-inducible wild-type 
C/EBPα (CEBPA) or C/EBPα-p30 (P30) isoform. As 
expected, doxycycline (Dox) treatment of CEBPA cells 
restored C/EBPα expression and induced proliferation 
arrest and granulocytic differentiation ([25–27], while the 
Dox treatment on control empty vector (CTR) cells and 
P30 cells had no effect on proliferation (Supplementary 
Information, Figure S1). RNA-seq analysis was performed 
to search for lncRNAs that might be differentially regulated 
by the two C/EBPα isoforms. RNAs were analyzed by 
strand-specific and paired-end deep sequencing from 
biological duplicates. The total number of sequenced reads 
ranged from 50–70 million pairs for sample with similar 
percentage of alignment. Statistical analysis confirmed a 
near 95% correlation between replicates (Supplementary 
Information, Figure S2). Transcripts were mapped and 
assembled to the human genome (hg19) using TopHat 
and Cufflinks [28], respectively. Cuffdiff [29] was used 
to test for differential expression on Cufflinks assembled 
transcripts. A false discovery rate of 0.1 was used to select 
bona fide statistically significant changes in expression 
levels. We used the scale “log (FPKM+1)” to graph on a 
log scale and account for genes that had an FPKM of zero 
in one of the samples. The analysis revealed a total of 
1079 protein coding RNAs and 170 lncRNAs in CTR vs 
CEBPA, 55 protein coding RNAs and 6 lncRNAs in CTR 
vs P30 and 949 protein coding RNAs and 155 lncRNAs in 
P30 vs CEBPA (Supplementary Information, Tables 
S1–S3). Significantly differentially expressed genes 
are showed in scatter plots (Figure 1A). A summary of 
all RNA biotypes used for this analysis can be seen in 
Supplementary Information, Figure S2. An unsupervised 
hierarchical clustering analysis on significant coding and 
non-coding transcripts with FPKM greater than 1 in either 
samples detected significant differences in expression 
between the three samples (Figure 1C). CTR vs CEBPA 
and P30 vs CEBPA were very similar and had almost 
identical distributions of protein coding and lncRNAs. This 
result reflects how the p30 isoform is inactive compared to 
wild type C/EBPα in transcriptional activity. Nevertheless, 
specific transcripts are modulated by the p30 isoform. 
We focused our analyses on the differentially expressed 
lncRNAs (Figures 1B and 1D). Interestingly, CTR vs P30 
produced few significant changes in lncRNA expression. 
Among them, we noticed up-regulation of the urothelial 
carcinoma associated 1 (UCA1), a well-known oncogenic 
lncRNA specifically induced in different types of solid 
tumors [21–24]. Our sequencing identified a single 2.3 kb 
UCA1 isoform, containing three exons, specifically up-
regulated by the p30 isoform and down-regulated by the 
wild type C/EBPα (Figures 2A and 2B). Real-time PCR 
analysis (qRT-PCR) confirmed that, with respect to control 
cells, higher levels of UCA1 expression were detected in 
P30 cells and decreased expression in CEBPA (Figure 2C). 
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Notably, UCA1 has opposite expression of well-known 
transcriptional targets of C/EBPα [25], confirming that our 
RNA-Seq data accurately reflect the activity of C/EBPα 
isoforms (Figure 2D).
To evaluate the significance of UCA1 in AML, 
we evaluated its expression in a public gene expression 
profiling by array from a cohort of cytogenetically 
normal AML patients containing 16 AML cases with 
biallelic CEBPA mutations (CEBPAdm) and 130 AML 
cases with wild type CEBPA [30]. In patients with 
CEBPAdm, one allele usually contains a mutation in 
the DNA-binding domain, whereas the other contains 
the mutation producing the p30 isoform [3]. Consistent 
with the data in K562 cell lines, there was a positive 
and significant correlation between UCA1 expression 
levels and CEBPA mutations (Figure 2E). While our 
studies were in progress, Bloomfield and co-workers 
reported a profiling of lncRNAs in cytogenetically 
Figure 1: Global transcriptome profiling via RNA-Seq. A. Pair-wise sample comparisons of differentially expressed coding genes, 
with red being significantly up-regulated and blue being significantly down-regulated. B. Pair-wise sample comparisons of differentially 
expressed lncRNAs, color coded the same as (A) An arrow indicates UCA1. C. This heatmap shows coding and non-coding genes 
significantly up-regulated or down-regulated between CTR, CEBPA and P30 cells as determined by CuffDiff, reported as fold change over 
mean. D. This heatmap shows differentially expressed lncRNAs as determined by CuffDiff, reported as fold change over mean.
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normal AML cells carrying mutations in the NPM1, 
CEBPA, IDH2, ASXL1, and RUNX1 genes and internal 
tandem duplications in the FLT3 gene [31]. Notably, 
in agreement with our study, UCA1 expression was 
found specifically induced in patients carrying CEBPA 
mutations. Taken together, these finding indicate that 
mutations in CEBPA can induce UCA1 expression 
in AML.
C/EBPα wild type and C/EBPα-p30 isoforms 
have opposite effect on UCA1 transcription
It has been previously shown that the UCA1 
promoter contains C/EBPα binding sites and that the 
C/EBPα protein can bind to the UCA1 promoter region 
both in vitro and in vivo in bladder cancer cells. However, 
in contrast of what we found in AML, C/EBPα seems to 
Figure 2: UCA1 expression levels in K562 cell lines and AML patients with CEBPA mutations. A. RNA-Seq read alignment 
of UCA1 is displayed. Previously identified CEBPB ChIP-Seq binding sites from ENCODE in K562 are depicted with a blue bar. B. FPKM 
values report from Cuffdiff differential gene expression analysis. C. Analysis of UCA1 expression levels amongst the CTR, CEBPA and 
P30 samples by qRT-PCR. D. Heatmap showing fold change over mean values of UCA1 along with other known transcription targets of 
C/EBPα. E. Quantitative expression analysis of UCA1 in primary leukemia cells derived from AML patients with biallelic CEBPA 
mutations (CEBPAdm) or wild-type CEBPA (CEBPA-wt). P value is indicated.
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regulate UCA1 in an opposite manner [32]. In addition, 
ENCODE Chromatin immunoprecipitation (ChIP) data 
sets (accession ENCSR000EHE) showed binding of 
C/EBPβ, which exhibit identical DNA-binding specificities 
with C/EBPα [33] in the UCA1 promoter region in K562 
cells. Thus, to analyze the transcriptional regulation of 
UCA1 expression by C/EBPα isoforms, we performed ChIP 
and promoter-luciferase assays in K562 cells.
To investigate whether C/EBPα isoforms physically 
interact in vivo with the UCA1 promoter, we performed 
ChIP on CTR-, CEBPA- and P30 -K562 cells with an 
anti-C/EBPα antibody that recognized both isoforms 
(Figure 3). DNA from the immunoprecipitates was 
amplified with a couple of PCR primers located in the 
promoter region surrounding the C/EBPα binding sites 
(Figure 4A; [24]) and normalised to the amplification 
obtained with oligonucleotides corresponding to an 
unrelated genomic region. Control IgGs were utilized as 
second negative control. Immunoprecipitation on UCA1 
promoters were detected with both wild-type C/EBPα and 
C/EBPα-p30 proteins while no signal was detected in CTR 
cells (Figures 3A and 3B). As expected, both C/EBPα 
isoforms can bind the UCA1 promoter since they share the 
same DNA binding capability [3]. ChIP performed with an 
antibody raised against the N-terminus of C/EBPα, which 
specifically recognized the p42 isoform, confirmed that 
the full-length C/EBPα proteins is able to bind the UCA1 
promoter (Figure 3B).
Furthermore, to assess the contribution of 
C/EBPα and C/EBPα p30 isoforms on UCA1 transcription 
we constructed promoter-luciferase fusion constructs 
containing the wild-type UCA1 promoter or a mutant 
derivative lacking the putative C/EBPα binding site 
and tested the resulting luciferase activity in K562 cells 
expressing C/EBPα or the individual p30 isoform (Figure 
3C). After transfection, cells were treated with Dox for 
48 hours to allow protein expression and luciferase activity 
was measured. Despite both isoforms being able to bind 
the UCA1 promoter, only the p30 was able to induce 
its transcription, whereas C/EBPα showed repressing 
activity. Moreover, a strong reduction in p30-mediated 
transcriptional activation was detected with the mutant 
luciferase-reporter in the C/EBPα binding site. Notably, 
wild-type C/EBPα continued to repress transcription 
of the mutant promoter. These results correlate with the 
RNA-seq and qRT-PCR data showing reduced UCA1 
expression in C/EBPα expressing cells compared to CTR 
cells (see Figures 2B and 2C). This might be explained 
by the activity of a transcriptional repressor induced by 
C/EBPα and not by p30 mutant that acts independently 
from C/EBPα protein on UCA1 promoter or by a 
differential binding of C/EBPα and p30 proteins on 
UCA1 promoter region. Taken together, these finding 
indicate that C/EBPα-p30 can specifically induce UCA1 
transcription through direct binding in its promoter region.
Knockdown of UCA1 decreases AML cell 
proliferation potential by inducing p27kip1 
expression
As UCA1 was shown to promote cell growth in 
different solid tumors [21, 34, 35], we then analyzed the 
pro-proliferation activity of UCA1 in AML cells. To do 
this, we utilized lentivirus infection to deliver short-hairpin 
RNA targeting UCA1 (shUCA1) alongside a control 
short-hairpin scramble sequence (shSCR) in our K562 
background cell line. We obtained about 60% reduction 
of UCA1 levels with shUCA1 that resulted in significant 
reduction of proliferation (Figures 4A and 4B). Cell cycle 
analysis revealed an increase in the G1 cell population 
and decrease in the S phase cell population upon shUCA1 
treatment (Figures 4C and 4D). Therein indicating that, 
similarly to other cancer cells, UCA1 is able to promote 
proliferation of AML cells.
After observing this block in proliferation and 
arrest in cell cycle progression, we sought to understand 
the mechanism by which UCA1 exerts its effects. One 
of the proposed mechanisms for UCA1 function was 
its capability to sequester hnRNP I protein, a positive 
translation regulator of the CDK inhibitor p27kip1, thus 
resulting in increased proliferation rate [23]. Therein, 
we analyzed p27kip1 protein levels after UCA1 knock-
down and observed an increase in p27kip1 protein levels 
in the shUCA1 cells when compared to the control 
shSCR cell line (Figure 4E). Next, we performed an 
RNA immunoprecipitation (RIP) using antibodies for 
hnRNP I and probing for UCA1 by qRT-PCR (Figure 4F). 
Notably, we observed a significant increase of UCA1 
levels with hnRNP I antibodies over IgG background 
levels, indicating an interaction of UCA1 and hnRNP I in 
K562 cells. Altogether these data indicate that UCA1 can 
contribute to the proliferation potential of AML cells by 
inhibiting p27kip1 expression.
DISCUSSION
The last decade has seen exciting developments in 
the field of lncRNAs, suggesting that the involvement of 
lncRNAs in human diseases could be far more prevalent 
than previously appreciated [15–17]. Different studies 
have shown that changes in lncRNA expression may 
contribute to the development of cancer ([18–19, 36–39]. 
It follows that identification of the molecular mechanisms 
that regulate lncRNAs is imperative to the understanding 
of the molecular mechanisms involved in tumorigenesis 
and in the future development of novel therapies aimed at 
targeting cancer cells.
Mutations in the CEBPA gene, encoding the C/
EBPα transcription factor, are observed in around 10% of 
AML cases and typically involve mutation of both CEBPA 
alleles [3]. The most common CEBPA mutation found 
in patients produces a short dominant negative isoform 
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referred to as p30. P30 can regulate unique set of target 
genes and is more than a dominant-negative regulator of 
C/EBPα function [4–7]. Various downstream effectors have 
been shown to contribute to C/EBPα p30 activity, including 
non-coding RNAs. At present, the majority of the studies 
have mainly focused on microRNAs. This study represents 
the first attempt to identify lncRNAs specifically regulated 
by C/EBPα mutant isoforms in AML. Utilizing AML cell 
lines modified to produce either wild type or C/EBPα-p30, 
we have assessed on a global transcriptome level via RNA 
Figure 3: C/EBPα-p30 regulates UCA1 expression. A. Schematic representation of the UCA1 promoter region, the putative 
C/EBPα binding site and oligonucleotides utilized in ChIP experiments are indicated. B. Chromatin from K562 cells was immunoprecipitated 
with anti-CEBPA antibodies recognizing both isoforms (left panel) or only the p42 (right panel), and the recovered DNA was quantified 
by real-time PCR. Results are expressed as the relative level over control cells after correcting for differences in the amount of starting 
(input) chromatin materials. The histograms represent the means ± S.E.M from three independent experiments. Binding sites for CEBPA 
and position of the qRT-PCR amplicon are indicated in the schematic representation. C. Schematic representation of the UCA1 promoter 
region and its mutant derivative in the putative C/EBPα binding site cloned in the pGL4 luciferase reporter vector. CTR, CEBPA, and P30 
cells were transfected with UCA1 wild type and mutant promoter reporters. FF luciferase values were normalized to RL luciferase reading 
and then normalized again to empty pGL4 vector to obtain the transcription efficiency. The histograms represent the means ± S.E.M. from 
three independent experiments.
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sequencing the effect these isoforms have on expression 
of lncRNAs. We were surprised to identify a well-known 
oncogenic lncRNA, UCA1 [21–24], which was specifically 
induced by the expression of the C/EBPα-p30 isoform. 
This was immediately interesting given the fact that the 
frame-shift mutation causing an over production of the 
dominant negative p30 isoform is seen in a significant 
percentage of AML patients [3]. Indeed, we observed a 
significant up-regulation of UCA1 expression in AML 
carrying CEBPA mutations. C/EBPα is a strong inducer 
Figure 4: UCA1 sustain AML cell proliferation and regulated p27kip1 expression. A. Effectiveness of UCA1 silencing in 
K562 cells. Level of expression was measure by qRT-PCR relative to HPRT mRNA. Error bars represent S.E.M., from three independent 
experiments, P < 0.05. B. Effect of shUCA1 and shSCR on cell proliferation. C. Cell cycle distribution of cells transduced with shUCA1 
and shSCR lentivirus. The histograms represent the means ± S.E.M. from three independent experiments. D. Representative cell cycle 
analysis of (C) E. Western blot analysis of p27kip1 protein levels from cells transduced with shUCA1 and shSCR lentivirus. GAPDH was 
utilized as loading control. F. RIP was performed on cytoplasmic extracts from K562 cells. The extracts were incubated with anti-hnRNP 
I (IP) or control antibodies (IgG). Beads-only were used as control (BO). The eluted RNA was analyzed by qRT-PCR. IP efficiency was 
assessed by western blot.
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of differentiation and cell proliferation arrest, however 
the p30 isoform lacks these abilities due to the absence 
of the N-terminus [3]. In particular, the p30 isoform lack 
the transcriptional activation domain that is present in the 
wild-type C/EBPα and thus it extremely interesting that this 
isoform is able to specifically induce the transcription of 
UCA1 lncRNA. Several publications have demonstrated 
that the p30 isoform is in fact capable of activating specific 
genes different from the full-length protein [4–7], however, 
it is still not clear how this is achieved. Further studies 
are needed to address these issues and to determine its 
therapeutic implications in AML.
In summary, our work identified, for the first time, an 
oncogenic long non-coding RNA functioning in concert with 
the dominant negative C/EBPα-p30 isoform in AML. Since 
the p30 isoform has transcriptional targets independent of the 
p42 isoform, it can be speculated that over-expression of the 
p30 isoform leads to activation of specific genetic programs 
that contribute to maintain cells in a state of proliferation, 
with UCA1 might play an integral role. Thus, we propose 
UCA1 as a novel diagnostic biomarker and a potential 
therapeutic target for AML with CEBPA mutations.
MATERIALS AND METHODS
Cell cultures and reagents
K562 cell lines were maintained in RPMI 1640 
medium supplemented with 1 × Penicillin/Streptomicin 
solution, 1 × L-glutamine and 10% Fetal Bovine Serum. 
Doxycycline (Dox) was purchased from Sigma and utilized 
at a concentration of 200 ng/ml, unless differently specified. 
Stable and inducible CEBPA, CEBPA-P30 and K562 cell 
lines were produced as previously described [25]. All utilized 
cell lines were tested for mycoplasma contamination.
RNA sequencing
Total RNA was extracted using TRIzol (Invitrogen) 
and the miRNeasy Mini Kit (Qiagen) according to 
manufacturer instructions. After ribosomal RNA depletion 
using RiboMinus (Life Technologies), the resulting RNA 
samples were then used as input for library construction 
using Illumina TruSeq stranded mRNA sample prep kit 
(RS-122-2101), as per manufacturer’s instructions. RNA 
libraries were then sequenced on the Illumina Genome 
Analyzer IIx (86 bp paired-end). For the second sequencing 
run, total RNA was sent to I.G.A. Applied Genomics Institute 
(Udine, IT) for library preparation using the Illumina 
TruSeq stranded mRNA sample prep kit (RS-122-2101) and 
subjected to sequencing on an Illumina HiSeq 2000 (100 bp 
paired-end). All RNA-seq data were aligned to hg19 genome 
using TopHat v2.0.12 with default parameters and assem- 
bled using Cufflinks 2.2.1 [28] and Gencode v.19 as 
reference file. We used Cuffdiff v2.2.1 [29] for all differential 
expression, with a false discovery rate (FDR) of 0.1.
Data access
The RNA-seq data have been deposited in NCBI’s 
Gene Expression Omnibus (GEO) [40] and are accessible 
through GEO Series accession number GSE65235.
RNA extraction and real-time qRT-PCR analysis
Total RNA was extracted using the miRNeasy Kit 
(Qiagen) according to manufacturer instructions. Reverse 
transcription to cDNA was performed with the SuperScript 
VILO cDNA Synthesis Kit (Life Technologies) according 
to the manufacturer instructions. Quantitative real-time 
PCR was performed on an Applied Biosystems 7500 
Fast Real Time PCR System. Reactions were performed 
in triplicate using the SYBR green dye detection system 
and analyzed using 7500 Software v2.0.6 (Applied 
Biosystems). Relative expression levels of targets 
were determined using the comparative 2∆∆Ct method. 
Hypoxanthine-guanine phosphoribosyltransferase (HPRT) 
mRNA was utilized as a reference.
UCA1 expression in primary AML samples
Values for UCA1 expression in primary 
cytogenetically normal AML with CEBPA mutations and 
wild-type CEBPA (AMLSG cohort; [30]) were obtained 
from available microarray analysis in GEO (DataSet 
GDS4278). P value was calculated using two-tailed Mann-
Whitney U-test.
Immunoblot analysis
40 μg of whole cell extract was separated by 10% 
SDS-PAGE and electroblotted to nitrocellulose membrane 
(Protran, S&S). Immunoblots were incubated with 
antibodies to C/EBPα (sc-61, Santa Cruz Biotechnology), 
p27kip1 (sc-528, Santa Cruz Biotechnology), hnRNPI 
(sc-56701, Santa Cruz Biotechnology) and GAPDH 
(sc-25778; Santa Cruz Biotechnology).
Promoter analysis
The region placed about 400 bp upstream the UCA1 
transcription start site was cloned upstream of the FF 
luciferase in pGL4-Basic Vector (Promega, Madison, WI, 
USA), giving rise to the UCA1-prom plasmid. Reporter 
plasmid carrying deletion of the CEBPA binding site 
(Mut-CEBPA) was obtained by reverse PCR using the 
oligonucleotides Mut-CEBPA-Fwd and Mut-CEBPA-Rev. 
1 μg of each pGL4 derivative plasmid (or an empty vector) 
and 50 ng of control pRL-TK vector were individually 
transfected into K562-CTR, K562-CEBPA, and K562-P30. 
At 12 h post-transfection, half of the cells were treated with 
dox for transgene expression. After 48 h of induction, cells 
were harvested and assayed with Dual Luciferase Assay 
(Promega) according to the manufacturer instructions.
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UCA1 knockdown
UCA1 knockdown was obtained by Mission 
Lentiviral shRNA clones targeting UCA1 (Sigma-Aldrich, 
USA). Mission Lentiviral Non-Targeting shRNA clone 
SHC002 (Sigma-Aldrich, USA) was utilized as control. 
Lentiviral particles were prepared according to the 
manufacturer’s specifications. Infection of AML cell lines 
was performed as previously described [41].
Chromatin immunoprecipitation assay
Protein/DNA cross-linking was obtained by 
incubating K562 cells for 10 minutes at 37°C in 
1% formaldehyde. After sonication, chromatin was 
immunprecipitated with 5 μg anti C/EBPα antibodies 
against (sc-61X and sc-9315X, Santa Cruz Biotechnology) 
as previously described [41]. Immunoprecipitation without 
specific antibody was performed as a negative control. 
Negative control amplifications were performed on an 
intergenic region of chromosome 4. The relative quantity 
of the immunoprecipitated factor at a locus was estimated 
using the quantitative threshold method [41].
RNA immunoprecipitation (RIP)
RIP was performed using 10 μg of hnRNP I antibody 
(Santa Cruz sc-56701) or isotypic IgGs (Santa Cruz sc-
2025) to 30 μl of Protein A/G salmon sperm agarose beads 
(Millipore) for 2 hr at 4°C. K562 lysates were prepared 
with 100 μl of RIPA buffer (100 mM NaCl, 20 mM Tris-
HCL pH 8, 0.5 5 mM EDTA, 0.5% NP-40) complemented 
with protease inhibitors and RNasin (Promega); 200 μg 
of each lysate was used for each RIP assay. Samples were 
precleared for 1 hr at 4°C with 30 μl of beads, and the 
supernatant was then resuspended in 600 μl IP buffer 
(50 mM Tris, pH 7.4, 150 mM NaCl, 1 mM MgCl2, 0.05% 
NP-40) and added to antibody-coated beads for 4 hr at 
4°C. Beads were washed with IP buffer five times and 
split for protein (1/3) and RNA analysis (2/3). Reactions 
were performed in triplicate using the SYBR green dye 
detection system and analyzed using serial dilutions of 
Input for the standard curve setting to determine absolute 
quantities of each sample. Fold change over background 
was determined as absolute quantity of IP/IgG.
Cell proliferation
Cell proliferation and viability was assessed using a 
Countess Automated Cell Counter (Life Technologies) and 
Tripan Blue exclusion assay according to manufacturer 
instruction. For cell cycle analysis, 2 × 105 cells were 
resuspended in PBS 50% FCS, fixed in 70% ethanol for 
24 hours, incubated with 50 μg/mL propidium iodide 
(Sigma-Aldrich) and 50 units/mL DNase free RNase 
A (Sigma-Aldrich), and analyzed after 3 hours (10, 000 
events) using an Epics XL Cytometer (Beckman Coulter). 
Data were analyzed with the FCS Express 4 Flow. A 
minimum of 10,000 events was collected for each sample 
with flow cytometer (CyAN ADP DAKO) by using 
Summit 4.3 software for data acquisition and analysis.
Oligonucleotides utilized in this study
qRT-PCR:
• UCA1: fwd 5′-GACCCTACCCGGTCATTTATAG-3′; rev 
5′-CTGATGGGCATGGCTTTATTC-3′.
• HPRT: QuantiTect Primer Assay QT00059066 (Qiagen).
ChIP:
• UCA1 promoter: fwd 5′-TCTCAGGCTGTCCTC- 
TGGGAAG-3′; rev 5′-TGTAGGCCACCTGGACATA- 
TATGTG-3′.
• Intergenic control: fwd 5′-TTATCTTGTGGATGTTAG-
GAAGCA-3′; rev 5′-AATCATGCAGATAATGACCA-
CATC-3′.
UCA1 promoter cloning for luciferase:
• UCA1-Fwd (Xho I): 5′-CCGCTCGAGAGAAAT-
GACCCAGGAGCTGAT -3′;
• UCA1-Rev (Hind III) - 5′-CCCAAGCTTGGTAGGCT-
GTGGAAAGTTAC-3′;
• Mut-CEBPA-Fwd - 5′-GGGAACTGTCAGGCCTCT-3′
• Mut-CEBPA-Rev- 5′-GTTACAGGGTGATGTGACCT-3′
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